The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 708K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

21 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.EBI
Kanazawa University
Involvement of organic anion-transporting polypeptides in the hepatic uptake of dioscin in rats and humans.EBI
Dalian Medical University
Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.EBI
University of North Carolina At Chapel Hill
In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.EBI
Glaxosmithkline
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.EBI
Universit£Tsmedizin G£Ttingen
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.EBI
Novartis Institutes For Biomedical Research
Structure-based identification of OATP1B1/3 inhibitors.EBI
Ku Leuven
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.EBI
Uppsala University
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.EBI
University Hospital
Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain.EBI
Bristol-Myers Squibb
Discovery of BMS-986339, a Pharmacologically Differentiated Farnesoid X Receptor Agonist for the Treatment of Nonalcoholic Steatohepatitis.EBI
Biocon-Bristol Myers Squibb Research and Development Center
Discovery of (EBI
Bristol-Myers Squibb
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPAEBI
Bristol Myers Squibb
Discovery of indoximod prodrugs and characterization of clinical candidate NLG802.EBI
Newlink Genetics
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.EBI
TBA
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.EBI
Pfizer
Precursor-Directed Biosynthesis and Fluorescence Labeling of Clickable Microcystins.EBI
University of Halle-Wittenberg
Interactions of glycyrrhizin with organic anion transporting polypeptides of rat and human liver.EBI
University of Zurich
Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.EBI
Chinese Academy of Sciences
Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.BDB
Cardiff University